Home›Companies›Biotech & Pharma›Nirrin

Nirrin Technologies, Inc.

Nirrin sells measurement instruments and analytics to biopharmaceutical development and manufacturing teams.

Updated Nov 10, 2026·Latest SEC filing Jun 15, 2026·Suggest an edit

About Nirrin

Nirrin is a private company based in Billerica, Massachusetts. It has reported $20,017,807 raised in three offerings on Form D since October 2021. Its chief executive is Bryan Hassell.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 23, 2025Jun 15, 2026$6,699,781of $9.7M target23$291KEquity, Options, Securities on exerciseRule 506(b)Form D ↗
Feb 1, 2024Feb 14, 2024$4,818,026of $6.0M target20$240KEquity, OptionsRule 506(b)Form D ↗
Oct 6, 2021Oct 20, 2021$8,500,000fully sold1$8.5MEquityRule 506(b)Form D ↗
Total, three offerings$20,017,807

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Nirrin's Form D filed Jun 15, 2026.

Earlier filings also listed Gregory Cresenzi (chief executive officer, last listed Feb 2024), Debrah Herman (chief financial officer, last listed Feb 2024), Jonathan Hartmann (chief executive officer and director, last listed Oct 2021) and John Ho (director, last listed Oct 2021).

Sources

  1. SECNirrin Technologies, Inc. filing history
  2. CompanyAbout Nirrin Technologies